Murine zcytor17 ligand polypeptides

• US 7,740,834 B2
• Filed: 01/29/2009
• Issued: 06/22/2010
• Est. Priority Date: 01/18/2002
• Status: Expired due to Fees

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Kuestner, Rolf E, Gross, Jane A., Sprecher, Cindy A., Hammond, Angela K., Grant, Francis J., Kuijper, Joseph L., Dasovich, Maria M.
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US12/362,318
• Publication Number:
  US 20090192292A1
• Time in Patent Office: 509 Days
• Field of Search: None
• US Class Current: 424/85.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

1. An isolated polypeptide comprising the sequence of amino acid residues having at least 96% sequence identity to:

(a) amino acid residues 31 to 163 as shown in SEQ ID NO;

11;

or

(b) amino acid residues 1 to 163 as shown in SEQ ID NO;

11.

2. The isolated polypeptide of claim 1 wherein the sequence of amino acid residues has at least 97% sequence identity to:

(a) amino acid residues 31 to 163 as shown in SEQ ID NO;

11;

or

(b) amino acid residues 1 to 163 as shown in SEQ ID NO;

11.

3. The isolated polypeptide of claim 1 wherein the sequence of amino acid residues has at least 98% sequence identity to:

(a) amino acid residues 31 to 163 as shown in SEQ ID NO;

11;

or

(b) amino acid residues 1 to 163 as shown in SEQ ID NO;

11.

4. The isolated polypeptide of claim 1 wherein the sequence of amino acid residues has at least 99% sequence identity to:

(a) amino acid residues 31 to 163 as shown in SEQ ID NO;

11;

or

(b) amino acid residues 1 to 163 as shown in SEQ ID NO;

11.

5. The isolated polypeptide of claim 1, wherein the polypeptide comprises a pharmaceutically acceptable carrier.

6. The isolated polypeptide of claim 1, wherein the polypeptide a recombinant polypeptide.

7. The isolated polypeptide of claim 6, wherein the recombinant polypeptide is produced in a prokaryotic cell.

8. The isolated polypeptide of claim 7, wherein the recombinant polypeptide is produced in E. coli.

9. The isolated polypeptide of claim 7, wherein the recombinant polypeptide is produced in a eukaryotic cell.

10. The isolated polypeptide of claim 9, wherein the recombinant polypeptide is produced in a mammalian cell.

11. The isolated polypeptide of claim 10, wherein the recombinant polypeptide is produced in a Chinese hamster ovary cell or in a baby hamster kidney (BHK) cell.

12. The isolated polypeptide of claim 1, wherein the polypeptide comprises an affinity tag.

13. The isolated polypeptide of claim 1, wherein the polypeptide comprises PEGylation.

14. The isolated polypeptide of claim 1, wherein amino acid residues at positions 74, 137, and 151 of SEQ ID NO:

11 are cysteine.

15. The isolated polypeptide of claim 2, wherein amino acid residues at positions 74, 137, and 151 of SEQ ID NO:

11 are cysteine.

16. The isolated polypeptide of claim 3, wherein amino acid residues at positions 74, 137, and 151 of SEQ ID NO:

11 are cysteine.

17. The isolated polypeptide of claim 4, wherein amino acid residues at positions 74, 137, and 151 of SEQ ID NO:

11 are cysteine.

18. An isolated antigenic polypeptide comprising a sequence of at least 30 contiguous amino acid residues of SEQ ID NO:

11, wherein the antigenic polypeptide comprises the amino acid sequence selected from;

(a) amino acid residues 34 to 39 of SEQ ID NO;

11;

(b) amino acid residues 46 to 51 of SEQ ID NO;

11;

(c) amino acid residues 131 to 136 of SEQ ID NO;

11;

(d) amino acid residues 158 to 163 of SEQ ID NO;

11; and

(e) amino acid residues 157 to 162 of SEQ ID NO;

11

and wherein the polypeptide induces proinflammatory cytokine production.

19. The isolated polypeptide of claim 18, comprising a sequence of from 30 to 100 contiguous amino acid residues of SEQ ID NO:

11.

20. An isolated protein produced by the method of culturing a cell comprising an expression vector comprising the following operably linked elements:

a) a transcription promoter;

(b) a DNA segment encoding the polypeptide comprising the sequence of amino acid residues 91 to 489 of SEQ ID NO;

10; and

(c) a transcription terminator under conditions wherein the DNA segment is expressed; and

recovering the protein encoded by the DNA segment.